Curis Inc. (CRIS)

Oncology Corporate Profile

Stock Performance

2.1400
0.0500

HQ Location

4 Maguire Road
Lexington, MA 2421

Company Description

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs.

Website: http://www.curis.com

Brand Generic Indication
Erivedge®vismodegibErivedge® (vismodegib) capsule is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CUDC-907HDAC/PI3K inhibitorDiffuse large B-cell Lymphoma (DLBCL)II
CA-4948IRAK4 inhibitorVarious cancer typesI
CA-170PLD1/VISTA antagonistVarious cancer typesI
CUDC-907HDAC/PI3K inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.curis.com

Recent News Headlines

Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

10/11/2016 01:06 pm

(Yahoo! Finance) Oct 11, 2016 - CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration.

Novartis Study Shows Skin Cancer Combo Also Works On Lungs

6/6/2016 02:00 pm

(Reuters) June 6, 2016 - A Novartis trial of two drugs against an aggressive lung cancer bodes well for broadening their use beyond melanoma, the Swiss drugmaker told the American Society of Clinical Oncology's conference in Chicago on Tuesday.

Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting

12/6/2015 02:39 pm

(TheStreet) Dec 6, 2015 - CUDC-907 (HDAC and PI3K inhibitor) demonstrates objective responses, including complete responses, in patients with relapsed/ refractory DLBCL with MYC alterations; Curis expects to initiate a randomized Phase 2 trial in patients with relapsed/refractory DLBCL with MYC alterations.

Drug Story

10/26/2015 11:01 am

(Harvard Gazette) Oct 23, 2015 - Americans often have no idea whether they’re getting value for their prescription drug dollars, something that has to change if costs are to be reigned in in this country, according to a panel at the Harvard T.H. Chan School of Public Health.

How Cancer Wreaks Havoc on Family Finances

10/26/2015 11:01 am

(U.S. News & World Report/HealthDay News) Oct 26, 2015 - A cancer diagnosis exacts an enormous toll on a person's health, and new research says it can also devastate a patient's ability to continue working and maintain financial stability.

A Cancer Diagnosis Can Lead to Significant Income Losses for Families

10/26/2015 06:05 am

(Wiley) Oct 26, 2015 - A new analysis indicates that when American adults are diagnosed with cancer, they experience significant decreases in the probability of working, in the number of hours they work, and correspondingly, in their incomes.

U.S. Drug Prices Should Reflect Value To Patients: Expert Panel

10/26/2015 06:05 am

(Reuters) Oct 23, 2015 - A panel of medical experts said on Friday the prices of prescription medicines in the United States need to be brought in line with the value they bring to patients instead of continuing to let drugmakers set any price they choose.

Drug Company Attempts $1 Alternative To Daraprim

10/23/2015 12:04 pm

(USA Today) Oct 23, 2015 - The fervor over a drug company’s decision to hike the price of a drug used to treat a potentially deadly parasitic disease has drawn at least one market competitor to attempt an alternative.

Northwest Bio Bothers British Bestie for Bounteous Bucks

10/23/2015 12:03 pm

(TheStreet) Oct 22, 2015 - British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.

VUMC and Incyte Corp. Form New Scientific Alliance

10/23/2015 12:03 pm

(VICC) Oct 22, 2015 - Vanderbilt University Medical Center (VUMC) investigators have joined forces with scientists at Incyte Corp. to explore new therapies for the treatment of various types of cancer, as well as other diseases. The company has agreed to help fund basic and translational science research by VUMC investigators.

Prevention Is Key in the 'War on Cancer'

10/23/2015 12:03 pm

(Medscape Medical News) Oct 22, 2015 - Understanding the causes of cancer as a foundation for prevention is central to success in the war on cancer in coming years, says Dr Christopher Wild, PhD, director of the International Agency for Research on Cancer (IARC), speaking at a one-day healthcare forum in London discussing how to measure success in combating the disease.

Bacon and Sausages as Big a Cancer Threat as Cigarettes, Say World Health Organisation

10/23/2015 12:02 pm

(Yahoo! News [UK]) Oct 23, 2015 - The World Health Organisation is planning to declare that bacon, sausages and other processed meats cause cancer.

Pre-Conferences Kick Off ACCC National Oncology Conference

10/23/2015 12:02 pm

(ACCCBuzz) Oct 22, 2015 - Cancer care professionals from across the country are gathering in Portland, Oregon, this week for the ACCC 32nd National Oncology Conference.

Association of Community Cancer Centers Announces 5th Annual Innovator Awards Winners

10/23/2015 12:02 pm

(ACCC) Oct 22, 2015 - Six cancer programs that have exhibited forward-thinking strategic planning and developed pioneering programs and creative solutions have received the Association of Community Cancer Centers (ACCC) 2015 Innovator Awards.

PharmaEngine Announces Taiwan FDA Approval of ONIVYDE (TM) (irinotecan Liposome Injection) for the Treatment of Metastatic Pancreatic Cancer

10/23/2015 12:02 pm

(TheStreet) Oct 22, 2015 - The Taiwan Food and Drug Administration (TFDA) is the first regulatory authority in the world granting the approval of ONIVYDE.

Updated Breast Cancer Screening Guidelines Unlikely to Affect Insurance Coverage

10/23/2015 12:02 pm

(KHN) Oct 23, 2015 - The American Cancer Society’s new breast cancer screening guidelines recommend that women start screening later and get fewer mammograms, but the change is unlikely to affect insurance coverage anytime soon.

ACS's Brawley: New Mammography Guideline Breaks Ground by Being Honest

10/23/2015 12:02 pm

(MedPage Today/The Gupta Guide) Oct 22, 2015 - The American Cancer Society's mammography screening guidelines published Tuesday in the Journal of the American Medical Association was "the result of one of the most significant things to come out of ACS since I started my tenure here 8 years ago," said Otis W. Brawley, MD, the society's chief medical officer.

Breast Screening Backlash

10/23/2015 12:02 pm

(Fred Hutch News Service) Oct 22, 2015 - Fred Hutch public health researcher Dr. Ruth Etzioni, a member of the ACS guidelines committee, joined us for a tweetchat to respond to the confusion, the criticism and the many, many questions.

Large Multi-Center Study Demonstrates Significant Increase in Detection of Esophageal Pre-Cancer With Use of WATS3D Biopsy

10/22/2015 11:05 am

(Yahoo! Finance) Oct 21, 2015 - CDx Diagnostics announced today new data from a prospective multi-center study of more than 12,800 patients demonstrating a significant increase in detection of esophageal pre-cancer, including Barrett's esophagus and dysplasia, with the use of WATS3D biopsy, a three dimensional computer-assisted biopsy system, in community-based settings.

Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

10/19/2015 11:30 am

(StreetInsider) Oct 19, 2015 - Curis, Inc. today announced the expansion of its pipeline with the addition of two programs, the first of which is an oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA), and the second is focused on inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4).

Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting

5/31/2015 07:01 pm

(TheStreet) May 31, 2015 - CUDC-907 (HDAC and PI3K Inhibitor) demonstrates objective responses, including complete responses, in patients with relapsed/refractory DLBCL; expansion phase ongoing in patients with relapsed/refractory DLBCL with recommended dose and schedule as monotherapy and in combination with standard dose of rituximab.

HPV Cancers in Men Take Off

2/18/2015 12:04 pm

(Scientific American) Feb 17, 2015 - A male-centric vaccination approach might be more effective at combating the STD.

Curis, Aurigene Partner to Develop Precision Oncology Targets

1/22/2015 11:34 am

(Pharmaceutical Business Review) Jan 22, 2015 - Curis and Aurigene Discovery Technologies have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets.

Data Presented on REVLIMID® (lenalidomide) Compared With Investigators' Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

12/9/2014 04:01 pm

(Celgene) Dec 8, 2014 - Celgene Corporation today announced that results were presented from a phase II/III study (DLC-001) of REVLIMID® (lenalidomide) compared with investigators' choice (IC) of therapy in patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL) were presented during the 56th American Society of Hematology annual meeting.

Curis Announces Re-Initiation of Patient Dosing in CUDC-427 Monotherapy Clinical Trial

6/5/2014 11:58 am

(StreetInsider.com) June 5, 2014 - Curis, Inc., an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that it has re-initiated dosing in the single-agent clinical trial of CUDC-427 in patients with advanced and/or refractory solid tumors or lymphomas.

Curis Announces Re-Initiation of Patient Dosing in CUDC-427 Monotherapy Clinical Trial

6/5/2014 06:05 am

(StreetInsider.com) June 5, 2014 - Curis, Inc., an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that it has re-initiated dosing in the single-agent clinical trial of CUDC-427 in patients with advanced and/or refractory solid tumors or lymphomas.

Congress Moves Forward with Increased Funding for the FDA in FY2015

5/30/2014 12:05 pm

(ASCO in Action) May 29, 2014 - The House Appropriations Committee on May 29 approved an Agriculture Appropriations bill allocating nearly $2.6 billion for the Food and Drug Administration (FDA) for fiscal year 2015.

Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014

4/8/2014 01:11 pm

(NASDAQ) Apr 7, 2014 - Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.

Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014

4/8/2014 01:09 pm

(Yahoo! Finance) Apr 7, 2014 - CUDC-907 modulates expression of certain cytokines/chemokines, potentially targeting tumor microenvironment in addition to direct effects on cancer cells; sensitivity to CUDC-427 may be predicted by alterations in TNF-alpha and XIAP expression.

Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014

4/8/2014 01:01 pm

(NASDAQ) Apr 7, 2014 - Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.

Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014

4/8/2014 01:00 pm

(Yahoo! Finance) Apr 7, 2014 - CUDC-907 modulates expression of certain cytokines/chemokines, potentially targeting tumor microenvironment in addition to direct effects on cancer cells; sensitivity to CUDC-427 may be predicted by alterations in TNF-alpha and XIAP expression.

FDA Lifts Clinical Hold on Curis Cancer Drug, Shares Surge

3/31/2014 10:01 am

(Xconomy Boston) Mar 31, 2014 - Curis’ cancer drug just got a second lease on life. Now the Lexington, MA-based company will have to make something of it.

FDA Lifts Clinical Hold on Curis Cancer Drug, Shares Surge

3/31/2014 10:00 am

(Xconomy Boston) Mar 31, 2014 - Curis’ cancer drug just got a second lease on life. Now the Lexington, MA-based company will have to make something of it.

Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting

12/9/2013 06:28 pm

(MarketWatch) Dec 9, 2013 - Curis, Inc., an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced preliminary first-in-human results from its ongoing Phase 1 trial of CUDC-907.

Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting

12/9/2013 06:02 pm

(MarketWatch) Dec 9, 2013 - Curis, Inc., an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced preliminary first-in-human results from its ongoing Phase 1 trial of CUDC-907.